- Home
- GENI vs PTGX Comparison
GENI vs PTGX Comparison
Compare GENI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENI
- PTGX
- Stock Information
- Founded
- GENI 2016
- PTGX 2006
- Country
- GENI United Kingdom
- PTGX United States
- Employees
- GENI N/A
- PTGX N/A
- Industry
- GENI Services-Misc. Amusement & Recreation
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- GENI Consumer Discretionary
- PTGX Health Care
- Exchange
- GENI Nasdaq
- PTGX Nasdaq
- Market Cap
- GENI 2.4B
- PTGX 2.9B
- IPO Year
- GENI N/A
- PTGX 2016
- Fundamental
- Price
- GENI $9.62
- PTGX $53.34
- Analyst Decision
- GENI Strong Buy
- PTGX Strong Buy
- Analyst Count
- GENI 13
- PTGX 9
- Target Price
- GENI $11.96
- PTGX $67.11
- AVG Volume (30 Days)
- GENI 3.9M
- PTGX 898.5K
- Earning Date
- GENI 08-05-2025
- PTGX 08-05-2025
- Dividend Yield
- GENI N/A
- PTGX N/A
- EPS Growth
- GENI N/A
- PTGX N/A
- EPS
- GENI N/A
- PTGX 0.86
- Revenue
- GENI $535,167,000.00
- PTGX $207,801,000.00
- Revenue This Year
- GENI $23.92
- PTGX N/A
- Revenue Next Year
- GENI $15.76
- PTGX $47.15
- P/E Ratio
- GENI N/A
- PTGX $62.27
- Revenue Growth
- GENI 22.89
- PTGX N/A
- 52 Week Low
- GENI $5.11
- PTGX $30.67
- 52 Week High
- GENI $11.40
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- GENI 46.68
- PTGX 58.33
- Support Level
- GENI $9.48
- PTGX $54.48
- Resistance Level
- GENI $10.50
- PTGX $57.18
- Average True Range (ATR)
- GENI 0.40
- PTGX 2.04
- MACD
- GENI 0.03
- PTGX -0.09
- Stochastic Oscillator
- GENI 32.95
- PTGX 57.13
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.